APO Research
Talk to an analyst

APO RESEARCH · REPORT

Regenerative Medicine

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body’s innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body’s innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.

Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

Selected research

Market Outlook & Growth Opportunities

Global Regenerative Medicine Market Outlook and Growth Opportunities 2026

21 December 2025215 pages

Choose your research edition.

Industry ResearchRegenerative Medicine Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Regenerative Medicine Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Regenerative Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Regenerative Medicine Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Regenerative Medicine Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body’s innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.

Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

Global Regenerative Medicine key players include J & J (DePuy Synthes), Medtronic, Allergan(Acelity), Zimmer Biomet, etc. Global top four manufacturers hold a share about 10%.

Read the full market overview

North America is the largest market, with a share about 25%, followed by Europe, and Asia Pacific, both have a share over 40 percent.

In terms of product, Tissue Engineering is the largest segment, with a share over 40%. And in terms of application, the largest application is Dermatology, followed by Cardiovascular, CNS, Orthopedic, etc.

This report provides an overview of the global Regenerative Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Regenerative Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Regenerative Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Regenerative Medicine market.

Regenerative Medicine Segment by Company

J & J (DePuy Synthes)

Medtronic

Zimmer Biomet

Stryker

Allergan(Acelity)

MiMedx Group

Organogenesis

Fujifilm Cellular Dynamics

Osiris Therapeutics

Vcanbio

CCBC

Cytori

Celgene

Vericel Corporation

Guanhao Biotech

Mesoblast

AMAG Pharmaceuticals (CBR)

ViaCord

CordLife

Integra LifeSciences

Nuvasive

Cook Biotech

Japan Tissue Engineering

Regenerative Medicine Segment by Type

Cell Therapy

Tissue Engineering

Biomaterial

Other

Regenerative Medicine Segment by Application

Dermatology

Cardiovascular

CNS

Orthopedic

Others

Regenerative Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Regenerative Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Regenerative Medicine key companies, revenue, market share, and recent developments.

3. To split the Regenerative Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Regenerative Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Regenerative Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Regenerative Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Regenerative Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Regenerative Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Regenerative Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Regenerative Medicine industry.

Chapter 3: Detailed analysis of Regenerative Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Regenerative Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Regenerative Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Regenerative Medicine Industry Trends Table 2. Regenerative Medicine Industry Drivers Table 3. Regenerative Medicine Industry Opportunities and Challenges Table 4. Regenerative Medicine Industry Restraints Table 5. Global Regenerative Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Regenerative Medicine Revenue Share by Company (2021-2026) Table 7. Global Regenerative Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Regenerative Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Regenerative Medicine Company, Product Type & Application Table 10. Global Regenerative Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Regenerative Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cell Therapy Table 15. Significant Companies of Tissue Engineering Table 16. Significant Companies of Biomaterial Table 17. Significant Companies of Other Table 18. Global Regenerative Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Regenerative Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Regenerative Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Regenerative Medicine Sales Value Share by Type (2021-2026) Table 22. Global Regenerative Medicine Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Dermatology Table 24. Significant Companies of Cardiovascular Table 25. Significant Companies of CNS Table 26. Significant Companies of Orthopedic Table 27. Significant Companies of Others Table 28. Global Regenerative Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Regenerative Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Regenerative Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Regenerative Medicine Sales Value Share by Application (2021-2026) Table 32. Global Regenerative Medicine Sales Value Share by Application (2027-2032) Table 33. Global Regenerative Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Regenerative Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Regenerative Medicine Sales Value Share by Region (2021-2026) Table 36. Global Regenerative Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Regenerative Medicine Sales Value Share by Region (2027-2032) Table 38. Global Regenerative Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Regenerative Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Regenerative Medicine Sales Value Market Share by Country (2021-2026) Table 41. Global Regenerative Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Regenerative Medicine Sales Value Market Share by Country (2027-2032) Table 43. J & J (DePuy Synthes) Company Information Table 44. J & J (DePuy Synthes) Business Overview Table 45. J & J (DePuy Synthes) Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. J & J (DePuy Synthes) Regenerative Medicine Product Portfolio Table 47. J & J (DePuy Synthes) Recent Development Table 48. Medtronic Company Information Table 49. Medtronic Business Overview Table 50. Medtronic Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Medtronic Regenerative Medicine Product Portfolio Table 52. Medtronic Recent Development Table 53. Zimmer Biomet Company Information Table 54. Zimmer Biomet Business Overview Table 55. Zimmer Biomet Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Zimmer Biomet Regenerative Medicine Product Portfolio Table 57. Zimmer Biomet Recent Development Table 58. Stryker Company Information Table 59. Stryker Business Overview Table 60. Stryker Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Stryker Regenerative Medicine Product Portfolio Table 62. Stryker Recent Development Table 63. Allergan(Acelity) Company Information Table 64. Allergan(Acelity) Business Overview Table 65. Allergan(Acelity) Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Allergan(Acelity) Regenerative Medicine Product Portfolio Table 67. Allergan(Acelity) Recent Development Table 68. MiMedx Group Company Information Table 69. MiMedx Group Business Overview Table 70. MiMedx Group Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. MiMedx Group Regenerative Medicine Product Portfolio Table 72. MiMedx Group Recent Development Table 73. Organogenesis Company Information Table 74. Organogenesis Business Overview Table 75. Organogenesis Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Organogenesis Regenerative Medicine Product Portfolio Table 77. Organogenesis Recent Development Table 78. Fujifilm Cellular Dynamics Company Information Table 79. Fujifilm Cellular Dynamics Business Overview Table 80. Fujifilm Cellular Dynamics Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Fujifilm Cellular Dynamics Regenerative Medicine Product Portfolio Table 82. Fujifilm Cellular Dynamics Recent Development Table 83. Osiris Therapeutics Company Information Table 84. Osiris Therapeutics Business Overview Table 85. Osiris Therapeutics Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Osiris Therapeutics Regenerative Medicine Product Portfolio Table 87. Osiris Therapeutics Recent Development Table 88. Vcanbio Company Information Table 89. Vcanbio Business Overview Table 90. Vcanbio Regenerative Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Vcanbio Regenerative Medicine Product Portfolio Table 92. Vcanbio Recent Development Table 93. CCBC Company Information Table 94. CCBC Business Overview Table 95. CCBC Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. CCBC Regenerative Medicine Product Portfolio Table 97. CCBC Recent Development Table 98. Cytori Company Information Table 99. Cytori Business Overview Table 100. Cytori Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Cytori Regenerative Medicine Product Portfolio Table 102. Cytori Recent Development Table 103. Celgene Company Information Table 104. Celgene Business Overview Table 105. Celgene Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Celgene Regenerative Medicine Product Portfolio Table 107. Celgene Recent Development Table 108. Vericel Corporation Company Information Table 109. Vericel Corporation Business Overview Table 110. Vericel Corporation Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Vericel Corporation Regenerative Medicine Product Portfolio Table 112. Vericel Corporation Recent Development Table 113. Guanhao Biotech Company Information Table 114. Guanhao Biotech Business Overview Table 115. Guanhao Biotech Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Guanhao Biotech Regenerative Medicine Product Portfolio Table 117. Guanhao Biotech Recent Development Table 118. Mesoblast Company Information Table 119. Mesoblast Business Overview Table 120. Mesoblast Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. Mesoblast Regenerative Medicine Product Portfolio Table 122. Mesoblast Recent Development Table 123. AMAG Pharmaceuticals (CBR) Company Information Table 124. AMAG Pharmaceuticals (CBR) Business Overview Table 125. AMAG Pharmaceuticals (CBR) Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 126. AMAG Pharmaceuticals (CBR) Regenerative Medicine Product Portfolio Table 127. AMAG Pharmaceuticals (CBR) Recent Development Table 128. ViaCord Company Information Table 129. ViaCord Business Overview Table 130. ViaCord Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 131. ViaCord Regenerative Medicine Product Portfolio Table 132. ViaCord Recent Development Table 133. CordLife Company Information Table 134. CordLife Business Overview Table 135. CordLife Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 136. CordLife Regenerative Medicine Product Portfolio Table 137. CordLife Recent Development Table 138. Integra LifeSciences Company Information Table 139. Integra LifeSciences Business Overview Table 140. Integra LifeSciences Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 141. Integra LifeSciences Regenerative Medicine Product Portfolio Table 142. Integra LifeSciences Recent Development Table 143. Nuvasive Company Information Table 144. Nuvasive Business Overview Table 145. Nuvasive Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 146. Nuvasive Regenerative Medicine Product Portfolio Table 147. Nuvasive Recent Development Table 148. Cook Biotech Company Information Table 149. Cook Biotech Business Overview Table 150. Cook Biotech Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 151. Cook Biotech Regenerative Medicine Product Portfolio Table 152. Cook Biotech Recent Development Table 153. Japan Tissue Engineering Company Information Table 154. Japan Tissue Engineering Business Overview Table 155. Japan Tissue Engineering Regenerative Medicine Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 156. Japan Tissue Engineering Regenerative Medicine Product Portfolio Table 157. Japan Tissue Engineering Recent Development Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Regenerative Medicine Product Image Figure 2. Global Regenerative Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Regenerative Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Regenerative Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cell Therapy Image Figure 8. Tissue Engineering Image Figure 9. Biomaterial Image Figure 10. Other Image Figure 11. Global Regenerative Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Regenerative Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Regenerative Medicine Sales Value Share by Type (2021-2032) Figure 14. Dermatology Image Figure 15. Cardiovascular Image Figure 16. CNS Image Figure 17. Orthopedic Image Figure 18. Others Image Figure 19. Global Regenerative Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Regenerative Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Regenerative Medicine Sales Value Share by Application (2021-2032) Figure 22. Global Regenerative Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Regenerative Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Regenerative Medicine Sales Value (2021-2032) & (US$ Million) Figure 25. North America Regenerative Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Regenerative Medicine Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Regenerative Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Regenerative Medicine Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Regenerative Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Regenerative Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. South America Regenerative Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Regenerative Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Regenerative Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Regenerative Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Regenerative Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Regenerative Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Therapy
  • Tissue Engineering
  • Biomaterial
  • Other
Applications
  • Dermatology
  • Cardiovascular
  • CNS
  • Orthopedic
  • Others
Companies covered
  • J & J (DePuy Synthes)
  • Medtronic
  • Zimmer Biomet
  • Stryker
  • Allergan(Acelity)
  • MiMedx Group
  • Organogenesis
  • Fujifilm Cellular Dynamics
  • Osiris Therapeutics
  • Vcanbio
  • CCBC
  • Cytori
  • Celgene
  • Vericel Corporation
  • Guanhao Biotech
  • Mesoblast
  • AMAG Pharmaceuticals (CBR)
  • ViaCord
  • CordLife
  • Integra LifeSciences
  • Nuvasive
  • Cook Biotech
  • Japan Tissue Engineering

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Regenerative Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Regenerative Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Regenerative Medicine Market Dynamics
  1. 2.1 Regenerative Medicine Industry Trends
  2. 2.2 Regenerative Medicine Industry Drivers
  3. 2.3 Regenerative Medicine Industry Opportunities and Challenges
  4. 2.4 Regenerative Medicine Industry Restraints
3 Regenerative Medicine Market by Company
  1. 3.1 Global Regenerative Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Regenerative Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Regenerative Medicine Company Ranking (2024-2026)
  4. 3.4 Global Regenerative Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Regenerative Medicine Company Product Type and Application
  6. 3.6 Global Regenerative Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Regenerative Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Regenerative Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Regenerative Medicine Market by Type
  1. 4.1 Regenerative Medicine Type Introduction
  2. 4.1.1 Cell Therapy
  3. 4.1.2 Tissue Engineering
  4. 4.1.3 Biomaterial
  5. 4.1.4 Other
  6. 4.2 Global Regenerative Medicine Sales Value by Type
  7. 4.2.1 Global Regenerative Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Regenerative Medicine Sales Value by Type (2021-2032)
  9. 4.2.3 Global Regenerative Medicine Sales Value Share by Type (2021-2032)
5 Regenerative Medicine Market by Application
  1. 5.1 Regenerative Medicine Application Introduction
  2. 5.1.1 Dermatology
  3. 5.1.2 Cardiovascular
  4. 5.1.3 CNS
  5. 5.1.4 Orthopedic
  6. 5.1.5 Others
  7. 5.2 Global Regenerative Medicine Sales Value by Application
  8. 5.2.1 Global Regenerative Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Regenerative Medicine Sales Value by Application (2021-2032)
  10. 5.2.3 Global Regenerative Medicine Sales Value Share by Application (2021-2032)
6 Regenerative Medicine Regional Value Analysis
  1. 6.1 Global Regenerative Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Regenerative Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Regenerative Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Regenerative Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Regenerative Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Regenerative Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Regenerative Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Regenerative Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Regenerative Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Regenerative Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Regenerative Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Regenerative Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Regenerative Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Regenerative Medicine Sales Value Share by Country, 2025 VS 2032
7 Regenerative Medicine Country-level Value Analysis
  1. 7.1 Global Regenerative Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Regenerative Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Regenerative Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Regenerative Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Regenerative Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Regenerative Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Regenerative Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Regenerative Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Regenerative Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Regenerative Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Regenerative Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Regenerative Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Regenerative Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Regenerative Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Regenerative Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Regenerative Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Regenerative Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Regenerative Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Regenerative Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Regenerative Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Regenerative Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Regenerative Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Regenerative Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Regenerative Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Regenerative Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Regenerative Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Regenerative Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Regenerative Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Regenerative Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Regenerative Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Regenerative Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Regenerative Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Regenerative Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Regenerative Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 J & J (DePuy Synthes)
  2. 8.1.1 J & J (DePuy Synthes) Company Information
  3. 8.1.2 J & J (DePuy Synthes) Business Overview
  4. 8.1.3 J & J (DePuy Synthes) Regenerative Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 J & J (DePuy Synthes) Regenerative Medicine Product Portfolio
  6. 8.1.5 J & J (DePuy Synthes) Recent Developments
  7. 8.2 Medtronic
  8. 8.2.1 Medtronic Company Information
  9. 8.2.2 Medtronic Business Overview
  10. 8.2.3 Medtronic Regenerative Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Medtronic Regenerative Medicine Product Portfolio
  12. 8.2.5 Medtronic Recent Developments
  13. 8.3 Zimmer Biomet
  14. 8.3.1 Zimmer Biomet Company Information
  15. 8.3.2 Zimmer Biomet Business Overview
  16. 8.3.3 Zimmer Biomet Regenerative Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zimmer Biomet Regenerative Medicine Product Portfolio
  18. 8.3.5 Zimmer Biomet Recent Developments
  19. 8.4 Stryker
  20. 8.4.1 Stryker Company Information
  21. 8.4.2 Stryker Business Overview
  22. 8.4.3 Stryker Regenerative Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Stryker Regenerative Medicine Product Portfolio
  24. 8.4.5 Stryker Recent Developments
  25. 8.5 Allergan(Acelity)
  26. 8.5.1 Allergan(Acelity) Company Information
  27. 8.5.2 Allergan(Acelity) Business Overview
  28. 8.5.3 Allergan(Acelity) Regenerative Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Allergan(Acelity) Regenerative Medicine Product Portfolio
  30. 8.5.5 Allergan(Acelity) Recent Developments
  31. 8.6 MiMedx Group
  32. 8.6.1 MiMedx Group Company Information
  33. 8.6.2 MiMedx Group Business Overview
  34. 8.6.3 MiMedx Group Regenerative Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MiMedx Group Regenerative Medicine Product Portfolio
  36. 8.6.5 MiMedx Group Recent Developments
  37. 8.7 Organogenesis
  38. 8.7.1 Organogenesis Company Information
  39. 8.7.2 Organogenesis Business Overview
  40. 8.7.3 Organogenesis Regenerative Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Organogenesis Regenerative Medicine Product Portfolio
  42. 8.7.5 Organogenesis Recent Developments
  43. 8.8 Fujifilm Cellular Dynamics
  44. 8.8.1 Fujifilm Cellular Dynamics Company Information
  45. 8.8.2 Fujifilm Cellular Dynamics Business Overview
  46. 8.8.3 Fujifilm Cellular Dynamics Regenerative Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fujifilm Cellular Dynamics Regenerative Medicine Product Portfolio
  48. 8.8.5 Fujifilm Cellular Dynamics Recent Developments
  49. 8.9 Osiris Therapeutics
  50. 8.9.1 Osiris Therapeutics Company Information
  51. 8.9.2 Osiris Therapeutics Business Overview
  52. 8.9.3 Osiris Therapeutics Regenerative Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Osiris Therapeutics Regenerative Medicine Product Portfolio
  54. 8.9.5 Osiris Therapeutics Recent Developments
  55. 8.10 Vcanbio
  56. 8.10.1 Vcanbio Company Information
  57. 8.10.2 Vcanbio Business Overview
  58. 8.10.3 Vcanbio Regenerative Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Vcanbio Regenerative Medicine Product Portfolio
  60. 8.10.5 Vcanbio Recent Developments
  61. 8.11 CCBC
  62. 8.11.1 CCBC Company Information
  63. 8.11.2 CCBC Business Overview
  64. 8.11.3 CCBC Regenerative Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CCBC Regenerative Medicine Product Portfolio
  66. 8.11.5 CCBC Recent Developments
  67. 8.12 Cytori
  68. 8.12.1 Cytori Company Information
  69. 8.12.2 Cytori Business Overview
  70. 8.12.3 Cytori Regenerative Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cytori Regenerative Medicine Product Portfolio
  72. 8.12.5 Cytori Recent Developments
  73. 8.13 Celgene
  74. 8.13.1 Celgene Company Information
  75. 8.13.2 Celgene Business Overview
  76. 8.13.3 Celgene Regenerative Medicine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Regenerative Medicine Product Portfolio
  78. 8.13.5 Celgene Recent Developments
  79. 8.14 Vericel Corporation
  80. 8.14.1 Vericel Corporation Company Information
  81. 8.14.2 Vericel Corporation Business Overview
  82. 8.14.3 Vericel Corporation Regenerative Medicine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Vericel Corporation Regenerative Medicine Product Portfolio
  84. 8.14.5 Vericel Corporation Recent Developments
  85. 8.15 Guanhao Biotech
  86. 8.15.1 Guanhao Biotech Company Information
  87. 8.15.2 Guanhao Biotech Business Overview
  88. 8.15.3 Guanhao Biotech Regenerative Medicine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Guanhao Biotech Regenerative Medicine Product Portfolio
  90. 8.15.5 Guanhao Biotech Recent Developments
  91. 8.16 Mesoblast
  92. 8.16.1 Mesoblast Company Information
  93. 8.16.2 Mesoblast Business Overview
  94. 8.16.3 Mesoblast Regenerative Medicine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Mesoblast Regenerative Medicine Product Portfolio
  96. 8.16.5 Mesoblast Recent Developments
  97. 8.17 AMAG Pharmaceuticals (CBR)
  98. 8.17.1 AMAG Pharmaceuticals (CBR) Company Information
  99. 8.17.2 AMAG Pharmaceuticals (CBR) Business Overview
  100. 8.17.3 AMAG Pharmaceuticals (CBR) Regenerative Medicine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AMAG Pharmaceuticals (CBR) Regenerative Medicine Product Portfolio
  102. 8.17.5 AMAG Pharmaceuticals (CBR) Recent Developments
  103. 8.18 ViaCord
  104. 8.18.1 ViaCord Company Information
  105. 8.18.2 ViaCord Business Overview
  106. 8.18.3 ViaCord Regenerative Medicine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 ViaCord Regenerative Medicine Product Portfolio
  108. 8.18.5 ViaCord Recent Developments
  109. 8.19 CordLife
  110. 8.19.1 CordLife Company Information
  111. 8.19.2 CordLife Business Overview
  112. 8.19.3 CordLife Regenerative Medicine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 CordLife Regenerative Medicine Product Portfolio
  114. 8.19.5 CordLife Recent Developments
  115. 8.20 Integra LifeSciences
  116. 8.20.1 Integra LifeSciences Company Information
  117. 8.20.2 Integra LifeSciences Business Overview
  118. 8.20.3 Integra LifeSciences Regenerative Medicine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Integra LifeSciences Regenerative Medicine Product Portfolio
  120. 8.20.5 Integra LifeSciences Recent Developments
  121. 8.21 Nuvasive
  122. 8.21.1 Nuvasive Company Information
  123. 8.21.2 Nuvasive Business Overview
  124. 8.21.3 Nuvasive Regenerative Medicine Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Nuvasive Regenerative Medicine Product Portfolio
  126. 8.21.5 Nuvasive Recent Developments
  127. 8.22 Cook Biotech
  128. 8.22.1 Cook Biotech Company Information
  129. 8.22.2 Cook Biotech Business Overview
  130. 8.22.3 Cook Biotech Regenerative Medicine Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Cook Biotech Regenerative Medicine Product Portfolio
  132. 8.22.5 Cook Biotech Recent Developments
  133. 8.23 Japan Tissue Engineering
  134. 8.23.1 Japan Tissue Engineering Company Information
  135. 8.23.2 Japan Tissue Engineering Business Overview
  136. 8.23.3 Japan Tissue Engineering Regenerative Medicine Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Japan Tissue Engineering Regenerative Medicine Product Portfolio
  138. 8.23.5 Japan Tissue Engineering Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst